Cargando…
Dysregulated lipid metabolism blunts the sensitivity of cancer cells to EZH2 inhibitor
BACKGROUND: Sensitivity has been a key issue for Enhancer of zeste homolog 2 (EZH2) inhibitors in cancer therapy. The EZH2 inhibitor EPZ-6438 was first approved by the US Food and Drug Administration (FDA) in 2020. However, its inadequate anti-cancer activity in solid tumors limits its clinical appl...
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850333/ https://www.ncbi.nlm.nih.gov/pubmed/35158113 http://dx.doi.org/10.1016/j.ebiom.2022.103872 |